US joins global recall of common heart drug over impurities

By Ben Hargreaves

- Last updated on GMT

(Image: iStock/Eartzen)
(Image: iStock/Eartzen)

Related tags Fda Ema valsartan Recall

The US FDA has joined other national regulatory bodies across the globe in recalling certain valsartan medicines, which were found to contain a probable carcinogen.

Earlier this month, the European Medicines Agency (EMA) announced that it was reviewing medicine containing valsartan and had advised national authorities to recall medicine​ containing the active ingredient.

The US Food and Drug Administration (FDA) has now taken the same step, after Zhejiang Hauhai had alerted authorities that it had discovered impurities in the ingredient that it produces.

The impurity is the ‘probable carcinogen’ N-nitrosodimethylamine; in regards to how this was introduced into the active ingredient, both the EMA and FDA suggested it had been introduced during a change in the manufacturing process.

When we approached the EMA to ascertain exactly what had changed and why this would see the impurity introduced, an EMA spokesperson stated that whilst the review is ongoing, the Agency could not provide further information.

The spokesperson clarified that once the review has been completed, the findings will be made public.

The FDA has named the companies which will engage in a voluntary recall of their products – it includes Teva Pharmaceuticals, Major Pharmaceuticals and Solco Healthcare for their valsartan medicine, and Teva and Solco for their valsartan/hydrochlorothiazide (HCTZ) medicine.

“We have carefully assessed the valsartan-containing medications sold in the US, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” ​said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, in a statement​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more